ENVOY MEDICAL DL-,0001 Aktie

Envoy Medical has completed enrollment of 56 patients in the pivotal US approval study of its fully implantable cochlear implant Acclaim and will collect 12 months of follow‑up data before filing a PMA application with the FDA. The company completed a public equity raise with immediate gross proceeds of $30 million and secured up to an additional $48 million via milestone‑dependent warrants; Nantahala Capital led the transaction. Preliminary six‑month data from the first 10 patients showed mean CNC word recognition improved from 15.2% to 39.2% with no reported study‑defined serious adverse events. Q1 revenue was $39,000, net loss $4.4 million, cash increased to about $25.3 million; R&D expenses rose to $3.6 million due to study activities. » Altro su de.investing.com

Envoy Medical has appointed Charles S. McKhann as a Class I director, expanding the board from six to seven members; his initial term runs until the 2027 annual meeting. McKhann was named to the compensation committee and will receive options on 100,000 common shares at an exercise price of $0.72, vesting over 36 months. The company highlights McKhann’s experience at Exagen, Distalmotion, Silk Road Medical and Apollo Endosurgery. In parallel, Envoy reported progress on the 12-month data from the Acclaim cochlea study, secured three new patents and, via a placement offering, initially raised $30 million in capital (with up to $48 million contingent on milestones); it also again meets Nasdaq’s minimum market value requirement. » Altro su de.investing.com

Envoy Medical received written confirmation from Nasdaq that the minimum requirement for the Market Value of Listed Securities has been met again after the company implemented strategic financing measures and strengthened its balance sheet. The medtech company, known for the Esteem middle-ear implant and the Acclaim cochlear implant in development, received a notice of noncompliance with exchange rules in February 2025. With a market capitalization of USD 53.51 million and most recently only USD 0.21 million in revenue, Envoy still shows high cash burn and a current ratio of 0.64, so financial risks remain. The company has a plan to maintain compliance and expects to remain listed on the Nasdaq Capital Market under the ticker COCH. » Altro su de.investing.com